Survey of Ophthalmology
Volume 45 , Pages S227-S239 , March 2001

The Treatment of Dry Eye

  • Margarita Calonge, MD

      Affiliations

    • Corresponding Author InformationReprint address: Prof. Margarita Calonge, IOBA-Facultad de Medicina, Universidad de Valladolid, Ramón y Cajal, 7, Valladolid 47005, Spain

References 

  1. Akramian J, Wedrich A, Nepp J, Sator M. Estrogen therapy in keratoconjunctivitis sicca. Adv Exp Med Biol. 1998;438:1005–1009
  2. Argueso P, Herreras JM, Calonge M, et al.  Analysis of human ocular mucus (effects of neuraminidase and chitinase enzymes). Cornea. 1998;17:200–207
  3. Avisar R, Robinson A, Appel I, et al.  Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000;19:145–147
  4. Avisar R, Savir H. Our further experience with bromhexine in keratoconjunctivitis sicca. Ann Ophthalmol. 1988;20:382
  5. Baldone JA, Kaufman HE. Extended wear contact lenses. Am J Ophthalmol. 1983;15:595–596[editorial]
  6. Becquet F, Goldschild M, Moldovan MS, et al.  Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:19–25
  7. Becquet F, Goldschild M, Moldovan MS, et al.  Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419–425
  8. Benson DR, Hemmady PB, Snyder RW. Efficacy of laser punctal occlusion. Ophthalmology. 1992;99:618–621
  9. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528–532
  10. Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg. 1999;125:561–566
  11. Boroojerdi B, Ferbert A, Schwarz M, et al.  Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998;65:111–114
  12. Bourcier T, De Saint-Jean M, Brignole F, et al.  Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Invest Ophthalmol Vis Sci. 2000;41:120–126
  13. Brignole F, Pisella PJ, Goldschild M, et al.  Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41:1356–1363
  14. Bron AJ, Daubas P, Siou-Mermet R, Trinquand C. Comparison of the efficacy and safety of two eye gels in the treatment of dry eyes (Lacrinorm and Viscotears). Eye. 1998;12:839–847
  15. Bron AJ, Mangat H, Quinlan M, et al.  Polyacrylic acid gel in patients with dry eyes (a randomised comparison with polyvinyl alcohol). Eur J Ophthalmol. 1998;8:81–89
  16. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25:15–30
  17. Carney LG, Hill RM. Human tear buffering capacity. Arch Ophthalmol. 1979;97:951–952
  18. Chen JL, Cyr GN. Compositions producing adhesion through hydration. In:  Manly RS editors. Adhesion in Biological Systems. New York: Academic Press; 1970;p. 163–167
  19. De Clerk LS, Bourgeois N, Krueger GRF, Stevens WJ. Human herpes virus 6 in Sjögrens syndrome. In:  Ablashi D,  Krueger GR,  Salahuddin SZ editor. Human Herpes Virus 6. Amsterdam: Elsevier Science Publishers; 1992;p. 303–315
  20. Dentinger PJ, Swenson CF, Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid. Am J Health Syst Pharm. 2000;57:1340–1342
  21. Diebold Y, Herreras JM, Callejo S, et al.  Carbomer- versus cellulose-based artificial-tear formulations (morphologic and toxicologic effects on a corneal cell line). Cornea. 1998;17:433–440
  22. Diestelhorst M, Grunthal S, Suverkrup R. Dry Drops (a new preservative-free drug delivery system). Graefes Arch Clin Exp Ophthalmol. 1999;237:394–398
  23. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970–2975
  24. Driot JY, Bonne C. Beneficial effects of a retinoic acid analog, CBS-211 A, on an experimental model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 1992;33:190–195
  25. Esmaeli B, Harvey JT, Hewlett B. Immunohistochemical evidence for estrogen receptors in meibomian glands. Ophthalmology. 2000;107:180–184
  26. Farris RL. Contact lenses and the dry eye. Int Ophthalmol Clin. 1994;34:129–136
  27. Felt O, Furrer P, Mayer JM, et al.  Topical use of chitosan in ophthalmology (tolerance assessment and evaluation of precorneal retention). Int J Pharm. 1999;180:185–193
  28. Ferraccioli GF, Salaffi F, De Vita S, et al.  Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogrens syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol. 1996;14:367–371
  29. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663
  30. Foulks GN. The now and future therapy of the non-Sjogrens dry eye. Adv Exp Med Biol. 1998;438:959–964
  31. Fox RI, Chan R, Michelson JB, et al.  Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–461
  32. Freeman JM. The punctum plug (evaluation of a new treatment for the dry eye). Trans Am Acad Ophthalmol Otolaryngol. 1975;79:OP874–OP879
  33. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92
  34. Gao J, Schwalb TA, Addeo JV. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca (the effect of topical cyclosporin A therapy). Cornea. 1998;17:654–663
  35. Geerling G, Honnicke K, Schroder C, et al.  Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye. Graefes Arch Clin Exp Ophthalmol. 2000;238:45–52
  36. Geerling G, Sieg P, Bastian GO, Laqua H. Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca. Ophthalmology. 1998;105:327–335
  37. Gilbard JP. Human tear film electrolyte concentrations in health and dry-eye disease. Int Ophthalmol Clin. 1994;34:27–36
  38. Gilbard JP, Huang AJ, Belldegrun R, et al.  Open-label crossover study of vitamin A ointment as a treatment for keratoconjunctivitis sicca. Ophthalmology. 1989;96:244–246
  39. Gilbard JP, Rossi SR. An electrolyte-based solution that increases corneal glycogen and conjunctival goblet-cell density in a rabbit model for keratoconjunctivitis sicca. Ophthalmology. 1992;99:600–604
  40. Gilbard JP, Rossi SR, Heyda KG. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. Am J Ophthalmol. 1989;107:348–355[see comments]
  41. Gilbard JP, Rossi SR, Heyda KG, Dartt DA. Stimulation of tear secretion by topical agents that increase cyclic nucleotide levels. Invest Ophthalmol Vis Sci. 1990;31:1381–1388
  42. Gilger BC, Rose PD, Davidson MG, et al.  Low-dose oral administration of interferon-alpha for the treatment of immune-mediated keratoconjunctivitis sicca in dogs. J Interferon Cytokine Res. 1999;19:901–905
  43. Glatt HJ. Acute dacryocystitis after punctal occlusion of keratoconjunctivitis sicca. Am J Ophthalmol. 1991;111:769–770[letter]
  44. Gobbels M, Selbach J, Spitznas M. Effect of eledoisin on tear volume and tear flow in humans as assessed by fluorophotometry. Graefes Arch Clin Exp Ophthalmol. 1991;229:549–552
  45. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogrens syndrome. Acta Ophthalmol (Copenh). 1994;72:438–442
  46. Guzman K, Gray TE, Yoon JH, Nettesheim P. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids. Am J Physiol. 1996;271:L1023–L1028
  47. Heiligenhaus A, Koch JM, Kemper D, et al: [Therapy of dry eye disorders]. Klin Monatsbl Augenheilkd 204:162–8, 1994
  48. Hunt G, Kearney P, Kellaway IW. Mucoadhesive polymers in drug delivery systems. In:  Johnson P,  Lloyd-Jones J editor. Drug Delivery Systems (Fundamentals and Techniques). Chichester, UK: Ellis Horwood Ltd; 1987;
  49. Ichikawa Y, Tokunaga M, Shimizu H. Clinical trial of ambroxol (Mucosolvan) in Sjogrens syndrome. Tokai J Exp Clin Med. 1988;13:165–169
  50. Jones BR, Coop HV. The management of keratoconjunctivitis sicca. Trans Ophthalmol Soc UK. 1965;85:379–390
  51. Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–346
  52. Kobayashi TK, Tsubota K, Takamura E, et al.  Effect of retinol palmitate as a treatment for dry eye (a cytological evaluation). Ophthalmologica. 1997;211:358–361
  53. Kunert KS, Tisdale AS, Stern ME. Effect of cyclosporine ophthalmic emulsion on the number of inflammatory cells and goblet cells in conjunctival biopsies with dry eye (abstract). Invest Ophthalmol Vis Sci. 1999;40(Suppl):S771
  54. Laibovitz RA, Solch S, Andriano K, et al.  Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315–323
  55. Lamberts DW. Punctal occlusion. Int Ophthalmol Clin. 1994;34:145–150
  56. Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol. 1988;19:209–211
  57. Lee SY, Ubels JL, Soprano DR. The lacrimal gland synthesizes retinol-binding protein. Exp Eye Res. 1992;55:163–171
  58. Lemp MA. The 1998 Castroviejo Lecture. New strategies in the treatment of dry- eye states. Cornea. 1999;18:625–632
  59. Lemp MA. Management of the dry-eye patient. Int Ophthalmol Clin. 1994;34:101–113
  60. Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg. 1999;15:S227–S231
  61. Li Q, Dunn ET, Grandmaison EW, Goosen MFA. Applications and properties of chitosan. J Bioact Comp Polym. 1992;7:370–397
  62. Linberg JV, Moore CA. Symptoms of canalicular obstruction. Ophthalmology. 1988;95:1077–1079
  63. Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology. 1999;106:939–943
  64. Lopez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier (effect of artificial tears and preservatives). Curr Eye Res. 1991;10:645–656
  65. Macri A, Rolando M, Pflugfelder S. A standardized visual scale for evaluation of tear fluorescein clearance. Ophthalmology. 2000;107:1338–1343
  66. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811–816
  67. Mathers WD, Dolney AM. Objective demonstration of tear stimulation with oral pilocarpine in dry eye patients. Invest Ophthalmol Vis Sci. 2000;41:S60
  68. Mathers WD, Stovall D, Lane JA, et al.  Menopause and tear function (the influence of prolactin and sex hormones on human tear production). Cornea. 1998;17:353–358
  69. Mundasad MV, Yerxa BR, Allgood VE. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in healthy subjects (abstract). Invest Ophthalmol Vis Sci. 2000;41(Suppl):S928
  70. Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant. 1996;18:641–642
  71. Murube J. Transplantation of salivary gland to the lacrimal basin. Scand J Rheumatol. 1986;61:264–267
  72. Murube J. Surgical treatment of the dry eye. In:  Boyd B editors. World Atlas Series of Ophthalmic Surgery, Vol. 2. Panama: Highlights of Ophthalmology International; 1995;p. 227–236
  73. Murube J, Murube A, Zhuo C. Classification of artificial tears. II (Additives and commercial formulas). Adv Exp Med Biol. 1998;438:705–715
  74. Murube J, Murube E. Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol. 1996;40:463–480
  75. Murube J, Olivares C, Murube E. Treatment of dry eye by punctum patch. Orbit. 1995;14:1–7
  76. Murube J, Paterson A, Murube E. Classification of artificial tears. I (Composition and properties). Adv Exp Med Biol. 1998;438:693–704
  77. Nelson JD, Friedlaender M, Yeatts RP, et al.  Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjogrens syndrome. The MGI PHARMA Sjogrens Syndrome Study Group. Adv Exp Med Biol. 1998;438:979–983
  78. Nepp J, Derbolav A, Haslinger-Akramian J, et al: [Effect of acupuncture in keratoconjunctivitis sicca (see comments)]. Klin Monatsbl Augenheilkd 215:228–32, 1999
  79. Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome. Eur J Pharm Biopharm. 1999;47:113–118
  80. Palmer SL, Bowen PA, Green K. Longitudinal tear study after cyclosporine in kidney transplant recipients. Ophthalmology. 1996;103:670–673
  81. Papas AS, Fernandez MM, Castano RA, et al.  Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogrens syndrome. Adv Exp Med Biol. 1998;438:973–978
  82. Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels. Pharm Res. 1987;4:457–464
  83. Pflugfelder SC. Advances in the diagnosis and management of keratoconjunctivitis sicca. Curr Opin Ophthalmol. 1998;9:50–53
  84. Pflugfelder SC, Jones D, Ji Z, et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogrens syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201–211
  85. Pisella PJ, Fillacier K, Elena PP, et al.  Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000;32:3–8
  86. Power WJ, Mullaney P, Farrell M, Collum LM. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogrens syndrome. Cornea. 1993;12:507–511
  87. Quarterman MJ, Johnson DW, Abele DC, et al.  Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49–54[see comments]
  88. Rapoza PA, Ruddat MS. Pyogenic granuloma as a complication of silicone punctal plugs. Am J Ophthalmol. 1992;113:454–455[letter]
  89. Redmond JW. Punctal occlusion with collagen implants. Ophthalmic Surg. 1992;23:642;[letter; comment]
  90. Rieger G. Lipid-containing eye drops (a step closer to natural tears). Ophthalmologica. 1990;201:206–212[see comments]
  91. Riemann R, Pfennigsdorf S, Riemann E, Naumann M. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland (a case report). Ophthalmology. 1999;106:2322–2324
  92. Rocha EM, Wickham LA, da Silveira LA, et al.  Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol. 2000;84:76–84
  93. Sahlin S, Chen E. Evaluation of the lacrimal drainage function by the drop test. Am J Ophthalmol. 1996;122:701–708
  94. Sahlin S, Chen E, Kaugesaar T, et al.  Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000;129:481–486
  95. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–639[published erratum appears in Ophthalmology 2000 Jul;107(7):1220]
  96. Selek H, Unlu N, Orhan M, Irkec M. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol. 2000;10:121–127
  97. Shimmura S, Goto E, Shimazaki J, Tsubota K. Viscosity-dependent fluid dynamics of eyedrops on the ocular surface. Am J Ophthalmol. 1998;125:386–388[published erratum appears in Am J Ophthalmol 1998 May;125(5):743]
  98. Ship JA, Fox PC, Michalek JE, et al.  Treatment of primary Sjogrens syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route (a phase II clinical trial. IFN Protocol Study Group). J Interferon Cytokine Res. 1999;19:943–951
  99. Singer L, Brook U, Romem M, Fried D. Vitamin A in Stevens-Johnson Syndrome. Ann Ophthalmol. 1989;21:209–210
  100. Smart JD, Kellaway IW, Worthington HE. An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery. J Pharm Pharmacol. 1984;36:295–299
  101. Smith RE, Taylor CR, Rao NA, et al.  Immunohistochemical identification of androgen receptors in human lacrimal glands. Curr Eye Res. 1999;18:300–309
  102. Sommer A. Xerophthalmia and vitamin A status. Prog Retin Eye Res. 1998;17:9–31
  103. Soong HK, Martin NF, Wagoner MD, et al.  Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study. Ophthalmology. 1988;95:1442–1446
  104. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjogrens syndrome (a preliminary report). J Rheumatol. 1997;24:1842–1843[see comments]
  105. Stamler JF, Tse DT. A simple and reliable technique for permanent lateral tarsorrhaphy. Arch Ophthalmol. 1990;108:125–127
  106. Steinfeld SD, Demols P, Van Vooren JP, et al.  Zidovudine in primary Sjogrens syndrome. Rheumatology (Oxford). 1999;38:814–817
  107. Stern ME, Beuerman RW, Fox RI. The pathology of dry eye (the interaction between the ocular surface and lacrimal glands). Cornea. 1988;17:584–589
  108. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease (a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group). Ophthalmology. 2000;107:967–974
  109. Sugita J, Yokoi N, Fullwood NJ. Detection of bacteria biofilm formation in punctal plug holes (abstract). Invest Ophthalmol Vis Sci. 2000;41(Suppl):S69
  110. Sullivan DA, Edwards JA. Androgen stimulation of lacrimal gland function in mouse models of Sjogrens syndrome. J Steroid Biochem Mol Biol. 1997;60:237–245
  111. Sullivan DA, Edwards JA, Wickham LA, et al.  Identification and endocrine control of sex steroid binding sites in the lacrimal gland. Curr Eye Res. 1996;15:279–291
  112. Sullivan DA, Krenzer KL, Sullivan BD, et al.  Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency?. Invest Ophthalmol Vis Sci. 1999;40:1261–1265
  113. Sullivan DA, Wickham LA, Rocha EM, et al.  Androgens and dry eye in Sjogrens syndrome. Ann NY Acad Sci. 1999;876:312–324
  114. Takaya M, Ichikawa Y, Yamada C, et al: [Treatment with pilocarpine hydrochloride for sicca symptoms in Sjogrens syndrome]. Ryumachi 37:453–7, 1997
  115. Terada K, Katamine S, Eguchi K, et al.  Prevalence of serum and salivary antibodies to HTLV-1 in Sjogrens syndrome. Lancet. 1994;344:1116–1119[see comments]
  116. Tiffany JM. Lipid-containing eye drops. Ophthalmologica. 1991;203:47–49[letter; comment]
  117. Tosti A, Tosti G. Thimerosal (a hidden allergen in ophthalmology). Contact Dermatitis. 1988;18:268–273
  118. Tripathi BJ, Tripathi RC. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res. 1989;6:395–403
  119. Tseng SC, Maumenee AE, Stark WJ, et al.  Topical retinoid treatment for various dry-eye disorders. Ophthalmology. 1985;92:717–727[published erratum appears in Ophthalmology 1989 May;96(5):730]
  120. Tsubota K. New approaches to dry-eye therapy. Int Ophthalmol Clin. 1994;34:115–128
  121. Tsubota K, Fujishima H, Toda I, et al.  Increased levels of Epstein-Barr virus DNA in lacrimal glands of Sjogrens syndrome patients. Acta Ophthalmol Scand. 1995;73:425–430
  122. Tsubota K, Goto E, Fujita H, et al.  Treatment of dry eye by autologous serum application in Sjogrens syndrome. Br J Ophthalmol. 1999;83:390–395[see comments]
  123. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984–1989
  124. Tsubota K, Monden Y, Yagi Y, et al.  New treatment of dry eye (the effect of calcium ointment through eyelid skin delivery). Br J Ophthalmol. 1999;83:767–770
  125. Tsubota K, Saito I, Ishimaru N, Hayashi Y. Use of topical cyclosporin A in a primary Sjogrens syndrome mouse model. Invest Ophthalmol Vis Sci. 1998;39:1551–1559
  126. Turner K, Pflugfelder SC, Ji Z, et al.  Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492–496[In Process Citation]
  127. Ubels JL, MacRae SM. Vitamin A is present as retinol in the tears of humans and rabbits. Curr Eye Res. 1984;3:815–822
  128. Ubels JL, McCartney MD, Lantz WK, et al.  Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol. 1995;113:371–378
  129. Vivino FB, Al-Hashimi I, Khan Z, et al.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome (a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group). Arch Intern Med. 1999;159:174–181
  130. Wee WR, Wang XW, McDonnell PJ. Effect of artificial tears on cultured keratocytes in vitro. Cornea. 1995;14:273–279
  131. Wenderlein IM, Clauder C. [Quality of life and estrogen therapy. Study of. 1996;716(women between 40 and 70 years of age]. Geburtshilfe Frauenheilkd 56):226–230
  132. Will DV, McNally LM, Roth RE. Pyogenic granuloma complicating ParasolTM (OdysseyTM) silicone punctal plug occlusion (a series review (abstract)). Invest Ophthalmol Vis Sci. 2000;41(Suppl):S69
  133. Willis RM, Folberg R, Krachmer JH, Holland EJ. The treatment of aqueous-deficient dry eye with removable punctal plugs. A clinical and impression-cytologic study. Ophthalmology. 1987;94:514–518
  134. Xie HP, Zhang HC. Effects of three kinds of topical eye-drops on the experimental rabbit dry eye. Chin Med J (Engl). 1993;106:196–201
  135. Yamada M, Kawai M, Mochizuki H, et al.  Fluorophotometric measurement of the buffering action of human tears in vivo. Curr Eye Res. 1998;17:1005–1009
  136. Yen MT, Monroy D, Pflugfelder SC. Punctal occlusion decreases tear production, clearance, and ocular surface sensation (abstract). Invest Ophthalmol Vis Sci. 1999;40(Suppl):S980
  137. Yerxa BR, Zhang VZ, Sheridan L. Cellular localization of P2Y2 receptor gene expression in primate tissues by nonisotopic in situ hybridization (abstract). Invest Ophthalmol Vis Sci. 2000;41(Suppl):S871

PII: S0039-6257(00)00205-8

Survey of Ophthalmology
Volume 45 , Pages S227-S239 , March 2001

Article Tools

* Image Usage & Resolution